Bremelanotide (PT-141) is a hydroxylated cyclic peptide structurally modified from Melanotan-2 as an active metabolite. In neurobehavioral animal models, it is used as a specific agonist to evaluate central autonomic nervous system activation via localized MC3R and MC4R receptor signaling.
